The biotechnology collaboration between Cuba and the Roswell Park Cancer Institute of the United States (RPCI) could be extended until November 30, 2027, after the renewal of the license issued by the U.S. authorities.
This was announced at a meeting between Cuban Deputy Prime Minister Jorge Luis Perdomo Di-Lella and Candace Johnson, president and CEO of the U.S. scientific center.
Perdomo Di-Lella thanked the close alliance of the RPCI with the Center for Molecular Immunology, in Cuba, in carrying out clinical studies of several drugs developed in the Cuban scientific institution for the treatment of cancer since 2011.
Candace Johnson said that the most significant achievement in recent years has been to create trusting relations between the companies on both sides, and on that basis to establish alliances.
She pointed out that Cuban scientists are very innovative and develop problem solving from different approaches; so many good things can come out of this bilateral collaboration.
Among the topics discussed was the RPCI's interest in taking advantage of the capacities to strengthen alliances with the Ministry of Public Health in the oncology area, with joint clinical research.
Carlos Fernández de Cossío, Vice Minister of Foreign Affairs; Dr. Eduardo Martínez Díaz, President of the BioCubaFarma business group, and other RPCI representatives also attended the meeting.
Translated by ESTI
